Disulfide bond formation is a key step in the manufacture of cysteine‑containing peptides, yet established oxidation…
The rising demands for therapeutic oligonucleotides requires scalable, efficient, and more sustainable manufacturing solutions. Stirred bed…
Oligonucleotides are emerging new therapeutic entities and reliable selective analytical methods to determine their purity and related impurities…
As demand for peptide-based APIs grows, selecting the most efficient and cost-effective manufacturing route is critical. In…
Linear synthesis by continuous-flow SPOS is the current state-of-the-art technology to manufacture oligonucleotide APIs. A very promising alternative,…
Recent years have seen drug recalls based on nitrosamine drug substance related impurities (NDSRIs), with medical agencies advising…
The expert panel discussion focused on evolving trends in the pharmaceutical industry, particularly the growing importance of external…
Peptides can be utilized as critical raw materials for in vitro diagnostics (IVD) to measure the presence or…
Linear synthesis by continuous-flow SPOS is the current state-of-the-art technology to manufacture oligonucleotide APIs. A very promising…
Developing peptide and oligonucleotide APIs demands a precise balance of efficiency, quality and compliance. To meet the growing…
